Confronto

Buserelin vs. Plecanatid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

57982-77-1

467426-54-6

Peso molecolare

1239.42 g/mol

1682 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Buserelin

Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Plecanatid

Plecanatide is structurally analogous to the body's own uroguanylin and, like it, activates the GC-C receptor at the gut surface, raising cGMP and fluid secretion. Its pH-dependent activity shifts the effect toward the proximal small intestine.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Buserelin	Plecanatid
Germania	Su prescrizione	Non approvato
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Buserelin and Plecanatid?: Buserelin is classified as "Ricerca (altro)", while Plecanatid is classified as "Ricerca (altro)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Plecanatid: Plecanatide is a 16-amino-acid analog of the body's own uroguanylin and a guanylate cyclase-C (GC-C) agonist. It is approved for chronic idiopathic constipation (CIC) and IBS with constipation (IBS-C). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Buserelin or Plecanatid?: The highest available evidence level is "RCT sull'uomo" for Buserelin and "RCT sull'uomo" for Plecanatid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Buserelin and Plecanatid in Germany and the United States?: Germania: Buserelin — Su prescrizione, Plecanatid — Non approvato. Stati Uniti: Buserelin — Non approvato, Plecanatid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Buserelin

Plecanatid

Germania

Su prescrizione

Non approvato

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between Buserelin and Plecanatid?

Buserelin is classified as "Ricerca (altro)", while Plecanatid is classified as "Ricerca (altro)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Plecanatid: Plecanatide is a 16-amino-acid analog of the body's own uroguanylin and a guanylate cyclase-C (GC-C) agonist. It is approved for chronic idiopathic constipation (CIC) and IBS with constipation (IBS-C). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Buserelin or Plecanatid?

The highest available evidence level is "RCT sull'uomo" for Buserelin and "RCT sull'uomo" for Plecanatid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Buserelin and Plecanatid in Germany and the United States?

Germania: Buserelin — Su prescrizione, Plecanatid — Non approvato. Stati Uniti: Buserelin — Non approvato, Plecanatid — Su prescrizione. These are factual summaries with source and review date on the individual pages.